Skip to main content

Table 2 Specifications of ART regimen, the incidence of dyslipidemia and pregnancy outcome in HIV-infected pregnancies (n = 17)

From: The association between HIV (treatment), pregnancy serum lipid concentrations and pregnancy outcomes: a systematic review

First author, Year

n

 

ART regimen

Grading of Dyslipidemia

% dyslipidemia

Pregnancy outcome

ART during ANC %

NRTI %

NNRTI %

PI%

All

TC

TG

HDL-C

PTB n(%)

Stillbirth n(%)

LBW n(%)

PE n(%)

Agostini 2008 [28]

29

100%

100%c

34.4%c

30.9%c

TC > 200, TG > 150 mg/dl

-

62.1

62.1

-

-

-

-

2 (6.9)

10a

100%

100%c

-

-

 

-

40.0

30.0

-

-

-

-

-

10a

100%

100%c

100%c

-

 

-

80.0

60.0

-

-

-

-

-

9a

100%

100%c

-

100%c

 

-

88.9

77.8

-

-

-

-

-

Areechokchai 2009 [41]

246

100%

   

UNS

1.2

-

-

-

25 (10.2)

1 (0.4)

49 (20)

4 (1.6)

40a

16.3% cART

100%a,b

>50%a

>20%a

 

7.5

-

-

-

(19.4)

-

0

3.2%

164a

66.7% PMTCT

99%a

99%d

-

 

0

-

-

-

(6.9)

-

0

-

42a

17.1% ART in labor

95.2%a

95.2%d

-

 

0

-

-

-

(19)

-

(19)

-

Bonafe 2013 [44]

32

100%

100%c

-

100%a

Grade III

-

-

6.3

-

(19.3)

-

-

-

31

100%

100%c

-

100%d

 

-

-

0

-

(17.8)

-

-

-

Cade 2015 [35]

16

100%

75%a/25%c

-

100%c

-

-

-

-

-

-

-

-

-

Calza 2012 [42]

21

100%

100%a

-

100%a

TC > 200, TG > 250 mg/dl

-

29

48

-

-

-

-

-

Duran 2006 [37]

271*

100%

-

-

-

Grade I/II

-

12.2/0

6.7/0.7

-

-

6 (1.7)

-

-

133a

49.1% cART

100%c

30.8%a

28.6%a

 

-

-

-

-

-

-

-

-

33a

12.2% PMTCT

100%a

-

-

 

-

-

-

-

-

-

-

-

El Beitune 2006 [29]

25

100%

100%a

-

100%a

-

-

-

-

-

-

-

-

-

20

100%

100%a

-

-

 

-

-

-

-

-

-

-

-

Floridia 2009 [26]

375

75.4%

UNS

22.9%a

39.9%c

TC > 240, TG > 200 mg/dl

-

25.6

24.5

6.2

-

-

-

-

86a

75.4%

UNS

100%a

-

 

-

-

-

-

-

-

-

-

Floridia 2014 [27]

322

100%

97.8%

-

100%a

-

-

-

-

-

69 (21.4)

(<2)

63 (20.8)

-

106

100%

98.1%

-

100%e

 

-

-

-

-

20 (18.9)

(<2)

24 (23.3)

-

Livingston 2007 [30]

81

100%

84/77%a

2.0%a

100%a

-

-

-

-

-

8 (10)

-

11 (14)

-

77

96.10%

88/91%a

52.0%a

-

 

-

-

-

-

5 (7)

-

9 (12)

-

Luzi, 2013

14

100%

100%a

7.1%c

92.9%c

-

-

-

-

-

-

-

-

-

Machado 2013 [31]

49

69%

-

-

-

UNS

0

-

-

-

-

-

-

-

Nasi 2011 [38]

68

100%

100%a,b

55.9%a

54.4%a

-

-

-

-

-

-

-

-

-

Omo-Aghoja 2010 [32]

154

100%

-

-

-

UNS

0

-

-

-

-

-

-

-

Peixoto 2011 [33]

164

100%

-

-

100%a

Grade III-IV

-

2.5

0.6

-

16 (9.8)

-

33 (20.2)

-

70

100%

-

-

100%d

 

-

8.6

0

-

6 (8.7)

-

11 (15.9)

-

Ramautarsing 2011 [36]

20

45%

100%c

-

100%a

Grade III

-

5

5

-

-

-

-

-

Santini-Oliveira 2014 [34]

27

100%

-

-

100%a

Grade I/II

-

11.1/7.4

3.7/7.4

-

2 (3.8)

-

(14.3)

-

26

100%

97.9%a

-

100%d

Grade I/II

-

15.4/7.7

7.7/3.9

-

2 (3.8)

-

(11.5)

-

  1. n: asubgroup of total study population, bcomponents of subgroup; (c)ART (combined) antiretroviral therapy; ANC antenatal care, PMTCT prevention of mother-to-child transmission; NRTI nucleoside reverse transcriptase inhibitor: alamivudine/zidovudine, b other, cnot specified, dstavudine; NNRTI non nucleoside reverse transcriptase inhibitor: aneviparine (NVP), bother, cnot specified, dsingle dose; PI protease inhibitor: aLPV/r or other first generation drug PI bother, cnot specified, dLPV/r increased dose of >800/200 mg/day), esecond generation PI; Atazanavir; TC total cholesterol, TG triglycerides, HDL-C high density lipoprotein-cholesterol; Pregnancy outcome; PTB preterm birth, LBW low birth weight, PE preeclampsia; *Duran et al. had data on ART in 293 cases, and data on adverse events (dyslipidemia) in 271 cases; Grading of dyslipidemia: Grade I-IV according to DAIDS [43]; UNS unspecified